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Abstract
Background: Monoacylglycerol lipase (MAGL), a critical lipolytic enzyme, has emerged as a key regulator of tumor
progression, yet its biological function and clinical significance in hepatocellular carcinoma (HCC) is still unknown.
Methods: In this study, we used a tissue microarray containing samples from 170 HCC patients to evaluate the
expression of MAGL and its correlation with other clinicopathologic characteristics. In addition, we investigated the
regulating effects of MAGL on various HCC lines. Finally, we identified the NF-κB signaling pathway participated in
MAGL-mediated epithelial-mesenchymal transition (EMT) using HCC cell lines with different metastatic potentials.
Results: The expression of MAGL was significantly higher in HCC tumors than in matched peritumor tissues.
Specifically, high MAGL expression was found in tumors with larger tumor size, microvascular invasion, poor
differentiation, or advanced TNM stage. In addition, the clinical prognosis for the MAGLhigh group was markedly
poorer than that for the MAGLlow group in the 1-, 3-, and 5-year overall survival times and recurrence rates of HCC
patients. MAGL expression was an independent prognostic factor for both survival and recurrence after curative
resection. Furthermore, the upregulation of MAGL in HCC cells promoted cell growth and invasiveness abilities, and
accompanied by EMT. In contrast, downregulation of MAGL obviously inhibited these characteristics. Moreover,
further investigations verified that MAGL facilitates HCC progression via NF-κB-mediated EMT process.
Conclusions: Our findings demonstrate MAGL could promote HCC progression by the induction of EMT and
suggest a potential therapeutic target, as well as a biomarker for prognosis, in patients with HCC.
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Background
Hepatocellular carcinoma (HCC) is the fifth most com-
mon malignancy and the second leading cause of
cancer-related deaths [1]. Tumor metastasis and recur-
rence is a critical contributor to the adverse prognosis
[2, 3]. Thus, a better understanding of biological charac-
teristics in HCC becomes urgently needed. Epithelial-
mesenchymal transition (EMT) is a program playing a
vital role in normal biological processes including embryo-
genesis, tissue remodeling, and wound healing [4, 5],
which also correlated with the acquisition of increased ag-
gressive and metastatic traits of tumor cells [6, 7]. To date,
increasing EMT-related transcription factors, such as
Snail, Twist, and Zeb1/2, are evidenced to be required in
the EMT trigger in tumor progression [8–11]. Neverthe-
less, the molecular mechanisms for the upstream of these
factors in HCC progression are not fully elucidated.
Therefore, uncovering the specific regulation mechanisms
of these factors may provide a new insight in therapeutic
strategies of HCC [12, 13].
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Monoacylglycerol lipase (MAGL) is a lipolytic enzyme
of lipid metabolism that catalyzes the conversion of
monoacylglycerides to free fatty acids (FFA) and glycerol.
MAGL plays a key role in several physiological processes
including pain and nociperception through hydrolysis of
the endocannabinoid 2-arachidonoylglycerol [14, 15].
Furthermore, MAGL also contributes to tumorigenesis
and metastasis. Emerging studies have identified that ex-
pression of MAGL is elevated in many types of cancers,
including melanoma, ovarian, and breast cancer [16].
MAGL could facilitate cancer cell proliferation and ag-
gressiveness through the production of signaling lipids
including monoacylglycerol (MAGs), FFA, and second-
ary lipid metabolites (especially LPA/PGE2). In addition,
MAGL was found to be part of a gene expression signa-
ture that contains many markers of EMT [17, 18]. In-
deed, EMT-related markers are predictors for increased
invasion, metastasis, and poor prognosis in some human
tumor types [19]. However, little is known about the
physiological role of MAGL in human HCC progression.
Here, we investigated the expression of MAGL in hu-
man HCCs and its clinical significance. In particular, we
explored the roles of MAGL in the growth and invasive-
ness of HCC cells in vivo and in vitro. We also verified
the signaling pathway by which MAGL promotes HCC
cell aggressiveness. Our findings provided the underlying
mechanism of MAGL in progression of HCC and sug-
gesting MAGL as a potential therapeutic target for
HCC.
Results
Expression of MAGL is upregulated in HCC patients and
associated with recurrence
To investigate the effects of MAGL in HCC, we first de-
tected MAGL expression in 27 tumor samples by immu-
nohistochemical assay and found that MAGL expression
was obviously elevated in HCC tissues compared with
paired peritumor tissues (Fig. 1a). Consistently, western
blot and qRT-PCR analysis of the indicated HCC pa-
tients demonstrated that the average expression of
MAGL on both protein and mRNA levels were signifi-
cantly higher in HCC tissues than peritumor tissues
(Fig. 1b, c). Interestingly, immunohistochemical analysis
for a large cohort of HCC samples (n = 170) showed that
the expression of MAGL was significantly elevated in
HCC patients with recurrence than those without recur-
rence (P = 0.001; Fig. 1d), which indicated a potential
role of MAGL in HCC progression.
MAGL overexpression predicts a poor clinical outcome of
HCC
To explore the clinical significance of MAGL expres-
sion in HCC, we further assessed the relationship be-
tween MAGL expression and the clinicopathologic
characteristics in a TMA of 170 HCC patients
(Table 1). Immunohistochemical analysis showed that
the average intensity of MAGL expression in tumor
was significantly higher than that in corresponding
peritumor tissues. Notably, elevated MAGL expression
was identified to be associated with larger tumor size
(P = 0.048), microvascular invasion (P = 0.026), poor
tumor differentiation (P = 0.012), and advanced TNM
stage (P = 0.001). Whereas the other clinicopathologic
characteristics, including age, gender, HbsAg, HCV,
liver cirrhosis, alpha-fetoprotein, tumor number, or
tumor encapsulation, showed no correlation with the
expression level of MAGL in HCC.
In the present study, all 170 HCC patients were di-
chotomized as MAGLlow expression (n = 77) and
MAGLhigh expression (n = 93), with MAGLhigh expres-
sion accounting for 54.7% (93 of 170). Moreover, pa-
tients in the MAGLhigh expression group exhibited
shorter OS than those in the MAGLlow expression
group (P = 0.003; Fig. 1e). Consistently, the 1-, 3-, and
5-year OS rates after surgery were much worse in the
MAGLhigh expression group than those in the MAGLlow
expression group (66.7 vs. 80.5%, 32.5 vs. 57.7%, 29.7 vs.
47.8%, respectively). In addition, the TTR in the MAGLlow
expression group was significantly lower than that in the
MAGLhigh expression group (P = 0.001; Fig. 1f), and the
1-, 3-, 5-year TTR rates were significantly higher in the
MAGLhigh group than in the MAGLlow group (13.4 vs.
9.4%, 66.7 vs. 44.6%, 87.4 vs. 58.5%, respectively). Univari-
ate and multivariate analysis indicated that MAGL was an
independent prognostic factor for both OS (HR =
1.628, P < 0.05) and TTR (HR = 1.593, P < 0.05; Tables 2
and 3). Thus, these data clearly revealed that MAGL is a
valuable predictive factor for clinical outcome of HCC.
MAGL enhances HCC cell growth and invasiveness in vivo
and in vitro
To investigate the exact biological role of MAGL in
HCC, we evaluated MAGL expression in various HCC
cell lines (HepG2, SMMC7721, Huh7, MHCC97L,
MHCC97H, and HCCLM3) and one normal liver cell
line (L0-2). Data showed that the protein and mRNA ex-
pression of MAGL were significantly upregulated in
HCC cell lines compared to in L0-2 cells (P < 0.05;
Fig. 2a, b). And the expression of MAGL was enhanced
in parallel with the increase of the metastatic potential
of HCC cells, with the lowest level in HepG2 cells and
the highest level in HCCLM3 cells. Then, MAGL ex-
pression in HepG2, a MAGLlow HCC cell line, was suc-
cessfully upregulated (HepG2-MAGL). Meanwhile, in
HCCLM3, a MAGLhigh HCC cell line was stably down-
regulated (HCCLM3-shMAGL) (Fig. 2c, d). Our data
showed that the growth of HepG2-MAGL cells in vivo
was significantly increased (3350.0 ± 250.0 vs. 2076.7 ±
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302.7 mm3, P < 0.01), whereas the growth of HCCLM3-
shMAGL cells was markedly restrained (626.7 ± 157.0 vs.
1756.7 ± 172.1 mm3, P < 0.01), compared to their re-
spective controls (HepG2-vector and HCCLM3-vector)
(Fig. 2e). Moreover, the wound healing and transwell
Matrigel invasion assays demonstrated that upregulation
of MAGL in HepG2 cells promoted its migratory and in-
vasive capacities, while HCCLM3-shMAGL cells with
decreased MAGL levels exhibited reduced motility and
invasiveness, compared with their respective controls
Fig. 1 Expression of MAGL is upregulated in HCC patients and its prognostic significance. a Representative immunostaining images of
MAGL levels in HCC tissues and corresponding peritumor tissues. Scale bar, 50 μm. MAGL levels were markedly higher in tumor tissues
than in peritumor tissues. b Western blot analysis of MAGL levels in HCC tissues and corresponding peritumor tissues. c The expression
of MAGL in 27 tumor samples were analyzed by qRT-PCR analysis. The average mRNA level of MAGL was significantly higher in tumor
tissues than in peritumor tissues. d Immunohistochemical staining analyses of MAGL expression in 170 HCC patients and representative
images are shown. Scale bar, 50 μm. e, f Kaplan–Meier analysis for overall survival and time to recurrence of HCC patients according to
MAGL expression. MAGL overexpression in HCC predicts poorer overall survival times and recurrence rates. Data, mean + SD. ***P < 0.001
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(HepG2-vector and HCCLM3-vector) (Fig. 2f, g). Evi-
dently, our results revealed that MAGL plays an import-
ant role in enhancing proliferative and invasive abilities
of HCC cells in vivo and in vitro.
MAGL promotes the progression of HCC by enhancing
EMT
To determine whether EMT contributes to the increased
HCC cell growth and invasion induced by MAGL, we
first identified the cellular morphology of HCC cell lines
with different MAGL expression levels (HepG2-vector,
HepG2-MAGL, HCCLM3-vector, and HCCLM3-
shMAGL). Results showed a significant difference in
morphology of the indicated cell lines (Fig. 3a). In this
study, HCC cells with higher MAGL levels (HepG2-
MAGL and HCCLM3-vector) exhibited a typical mesen-
chymal appearance which was more dispersed and
presented a spindle-like morphology, while HepG2-
vector and HCCLM3-shMAGL cells showed a distinct
epithelial morphology which took on a clustered and
cobblestone-like appearance. These results suggested
that MAGL might be closely correlated with EMT
process in HCC. To confirm whether EMT is essential
in the enhanced invasiveness of HCC cells mediated by
MAGL, we explored EMT markers by western blot and
qRT-PCR analysis in the indicated HCC cells. We found
that E-cadherin expression was markedly downregulated
in HepG2-MAGL and HCCLM3-vector cells, while mes-
enchymal markers, including N-cadherin and the key
EMT regulator Snail, were obviously upregulated com-
pared with their respective controls (HepG2-vector and
HCCLM3-shMAGL) (Fig. 3b–d and f). However, no sig-
nificant differences were observed in other EMT
markers such as vimentin and twist between groups with
different MAGL levels (Fig. 3b, e, and g). Consistently,
this phenomenon has also been observed in subcutane-
ous tumor samples by immunohistochemistry assay. Our
data revealed an obvious reduction of E-cadherin expres-
sion in HepG2-MAGL group, with markedly upregu-
lated expression of MAGL, N-cadherin, and Snail,
compared to HepG2-vector group (Fig. 3h). Collectively,
our data verified that MAGL overexpression might help
HCC cells acquire EMT-like biochemical traits, which
may contribute to MAGL-induced HCC cell growth and
invasiveness.
MAGL activated the NF-κB signal pathway in HCC cells
It is increasingly appreciated that NF-κB signaling
pathway plays a vital role in the tumor EMT process
[20–22]. To uncover how MAGL affects the process of
EMT, we assessed the activity of EMT-related molecules
by western blot analysis in HCC cells. We found that the
expression of NF-κB p65 was markedly increased in
HepG2-MAGL cells but significantly reduced in
HCCLM3-shMAGL cells compared to their respective
controls (Fig. 4a, b), suggesting that NF-κB signaling
might be responsible for MAGL-regulated HCC progres-
sion. To identify this hypothesis, we treated HepG2-
MAGL cells with MAGL-inhibitor JZL184 for various
Table 1 Clinical characteristics of 170 HCC patients and
correlation with MAGL staining
MAGL staining
Variables Low (n = 77) n(%) High (n = 93) n(%) P
Gender
Male 67 (87.0) 78 (83.9) 0.565
Female 10 (13.0) 15 (16.1)
Age(years)
≤50 28 (36.4) 37 (39.8) 0.648
>50 49 (63.6) 56 (60.2)
HBsAg
Negative 14 (18.2) 11 (11.8) 0.244
Positive 63 (81.8) 82 (88.2)
HCV
Negative 74 (96.1) 91 (97.8) 0.659
Positive 3 (3.9) 2 (2.2)
Liver cirrhosis
No 30 (39.0) 29 (31.2) 0.289
Yes 47 (61.0) 64 (68.8)
AFP(ng/ml)
≤20 28 (36.4) 23 (24.7) 0.099
>20 49 (63.6) 70 (75.3)
Tumor number
Single 56 (72.7) 55 (59.1) 0.064
Multiple 21 (27.3) 38 (40.9)
Tumor size(cm)
≤5 44 (57.1) 39 (41.9) 0.048
>5 33 (42.9) 54 (58.1)
Tumor encapsulation
Complete 37 (48.1) 49 (52.7) 0.547
Incomplete 40 (51.9) 44 (47.3)
Microvascular invasion
Absent 48 (62.3) 42 (45.2) 0.026
Present 29 (37.7) 51 (54.8)
Edmondson grade
I–II 16 (20.8) 36 (38.7) 0.012
III–IV 61 (79.2) 57 (61.3)
TNM stage
I 18 (23.4) 5 (5.4) 0.001
II–III 59 (76.6) 88 (94.6)
HBsAg hepatitis B surface antigen, HCV hepatitis C virus, AFP alpha fetoprotein,
TNM tumor node metastasis, MAGL monoacylglycerol lipase
Italic numbers means P < 0.05
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time periods and found the total protein expression of
NF-κB p65 was downregulated in a time-dependent
manner (Fig. 4c). Consistently, the expression of phos-
phorylated NF-κB p65 was also reduced in a time-
dependent manner when treated with JZL184 (Fig. 4d),
suggesting that MAGL could affect the activation of NF-
κB signaling in HCC cells. Furthermore, our data
showed that the level of NF-κB p65 protein in the nu-
cleus was detected to be downregulated in a time-
dependent manner, whereas this phenomenon was not
observed in cytoplasm (Fig. 4e, f ), suggesting that
MAGL-inhibitor JZL184 could inhibit the translocation
of NF-κB p65 protein into the nucleus, thus decreased
the total expression level of NF-κB p65. Evidently, our
results clearly displayed that MAGL-inhibitor JZL184
could inhibit upregulation, phosphorylation, and nuclear
translocation of NF-kB p65 in HCC cells, which means
that MAGL overexpression could promote the activity
of NF-kB p65 in HCC cells.
MAGL facilitates EMT via the NF-κB signaling pathway
To identify whether NF-κB pathway participated in
the effects of MAGL on HCC cells, we blockaded the
activation of NF-κB p65 using NF-κB p65-shRNA in
HepG2-MAGL cells (P < 0.001; Fig. 5a, b). As ex-
pected, we found that the increased expression of
Table 3 Multivariate analyses of factors associated with OS and TTR
OS TTR
Variablesa HR (95% CI) P HR (95% CI) P
HBsAg (negative vs. positive) NA 1.342 (0.700–2.573) 0.377
Liver cirrhosis (no vs. yes) 1.278 (0.795–2.053) 0.311 1.356 (0.855–2.149) 0.195
AFP (≤20 vs. >20 ng/ml) 1.487 (0.915–2.418) 0.110 NA
Tumor number (single vs. multiple) 1.642 (1.063–2.534) 0.025 1.671 (1.082–2.582) 0.021
Tumor size (≤5 vs. >5 cm) 2.712 (1.447–5.083) 0.002 1.874 (1.009–3.481) 0.047
Tumor encapsulation (complete vs. incomplete) 1.504 (0.988–2.289) 0.057 NA
Microvascular invasion (absent vs. present) 0.711 (0.385–1.315) 0.277 0.775 (0.419–1.436) 0.418
Edmondson grade (I–II vs. III–IV) 1.574 (0.989–2.504) 0.056 NA
TNM stage (I vs. II–III) 1.023 (0.444–2.358) 0.957 1.726 (0.687–4.340) 0.246
MAGL (low vs. high) 1.628 (1.020–2.597) 0.041 1.593 (1.011–2.510) 0.045
OS overall survival, TTR time to recurrence, HR hazard ratio, CI confidence interval, HBsAg hepatitis B surface antigen, AFP alpha fetoprotein, TNM tumor node
metastasis, MAGL monoacylglycerol lipase, NA not adopted
aVariables were adopted for their prognostic significance by multivariate analysis using the Cox proportional hazards regression model
Italic numbers means P < 0.05
Table 2 Univariate analyses of factors associated with OS and TTR
OS TTR
Variablesa HR (95% CI) P HR (95% CI) P
Gender (male vs. female) 1.375 (0.751–2.518) 0.302 1.072 (0.605–1.898) 0.811
Age (≤50 vs. >50 years) 0.863 (0.577–1.289) 0.471 1.140 (0.748–1.738) 0.542
HBsAg (negative vs. positive) 1.444 (0.788–2.646) 0.234 1.833 (0.974–3.449) 0.061
HCV (negative vs. positive) 1.157 (0.365–3.669) 0.805 0.612 (0.150–2.503) 0.494
Liver cirrhosis (no vs. yes) 1.337 (0.865–2.067) 0.192 1.476 (0.947–2.299) 0.085
AFP (≤20 vs. >20 ng/ml) 1.408 (0.893–2.219) 0.140 1.005 (0.650–1.553) 0.983
Tumor number (single vs. multiple) 1.731 (1.160–2.581) 0.007 1.877 (1.247–2.826) 0.003
Tumor size (≤5 vs. >5 cm) 2.211 (1.461–3.345) <0.001 1.936 (1.278–2.934) 0.002
Tumor encapsulation (complete vs. incomplete) 1.566 (1.049–2.338) 0.028 1.116 (0.744–1.676) 0.595
Microvascular invasion (absent vs. present) 1.602 (1.074–2.389) 0.021 1.556 (1.033–2.345) 0.035
Edmondson grade (I–II vs. III–IV) 1.401 (0.898–2.184) 0.137 1.282 (0.826–1.990) 0.268
TNM stage (I vs. II–III) 2.117 (1.026–4.369) 0.042 3.260 (1.423–7.468) 0.005
MAGL (low vs. high) 1.856 (1.220–2.823) 0.004 2.040 (1.331–3.128) 0.001
OS overall survival, TTR time to recurrence, HR hazard ratio, CI confidence interval, HBsAg hepatitis B surface antigen, HCV hepatitis C virus, AFP alpha fetoprotein,
TNM tumor node metastasis, MAGL monoacylglycerol lipase
aVariables were analyzed by Cox proportional hazards regression model
Italic numbers indicates that the variables might be associated with OS or TTR were subjected to the multivariate Cox analysis with 0.2 level for entry into the model
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Fig. 2 (See legend on next page.)
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Snail, a key EMT regulator, could markedly be reversed at
both protein and mRNA levels by NF-κB p65-shRNA treat-
ment (P < 0.01; Fig. 5a, c), while the enhanced expression
levels of MAGL displayed no obvious changes (Fig. 5a, d).
Furthermore, the wound healing and transwell Matrigel in-
vasion assays showed that downregulation of NF-kB p65 in
HepG2 cells with high MAGL expression could signifi-
cantly inhibited MAGL-induced motility and invasiveness
of HCC cells (P < 0.01; Fig. 5e, f). Collectively, these results
suggested that NF-κB pathway was involved in MAGL-
mediated EMT and contributed to the effects of HCC cells
induced by MAGL.
Discussion
Alterations in lipid metabolism for cancer cells are increas-
ingly being recognized. Cancer cells require fatty acids for
energy storage, membrane proliferation, and generation of
signaling molecules [23]. However, less is known about the
metabolic pathway that confers aggressive properties, in-
cluding high migratory and invasive abilities, on malignant
cancers. The present study demonstrated that MAGL is
distinctly upregulated and plays a positive role in HCC pro-
gression, which might represent a new link between the
metabolic signature and tumor progression.
In this study, we used a large cohort of HCC samples
to show that MAGL is expressed higher in HCC tissues
than in peritumor tissues, and the MAGL expression
was significantly associated with larger tumor size,
microvascular invasion, tumor differentiation, and TNM
stage. These observations were in accordance with previ-
ous reports in other malignancies such as prostate and
colorectal cancer [17, 24, 25]. Furthermore, our survival
analysis indicated that HCC patients with high expres-
sion of MAGL generally had even worse prognosis than
those with low expression. MAGL expression was
proved to be an independent prognostic factor for both
recurrence and survival after curative resection. Our
findings strongly imply MAGL as a marker for HCC ag-
gressiveness and is predictive for prognosis of HCC.
Meanwhile, we found that upregulation of MAGL
could promote in vivo growth and in vitro invasiveness
of HCC cells, and this process was accompanied with
EMT. EMT is a program that endows tumor cells with
stem-like properties, including self-renewal, enhanced
survival, and anchorage-independent growth [26]. After
undergoing EMT program, epithelial tumor cells
could acquire enhanced invasive and metastatic traits,
which was associated with high-grade malignancy. In
this study, the morphological characteristics in HCC
cells with MAGL overexpression transformed from
epithelial to mesenchymal, and the mesenchymal
markers were remarkably upregulated while the epi-
thelial markers were significantly decreased. In con-
trast, HCC cells with low MAGL expression exhibited
opposite features, which suggested that MAGL could
enable HCC cells to acquire mesenchymal-like traits,
and thus promote HCC aggressiveness. These effects
have previously been reported in other tumor cell
lines [27]. Our findings further confirmed the effects.
Taken together, our study demonstrated that MAGL
could promote HCC cell aggressiveness through, at
least partially, induction of EMT.
To date, multiple signaling pathways have been evi-
denced to be involved in EMT process, including NF-
κB, Hedgehog signaling, MAPKs, and so on. In this
study, we verified that the activation of NF-κB p65 in
HCC cells could be modulated by MAGL-inhibitor
JZL184. Furthermore, MAGL-induced EMT in HCC
cells was found to be carried out by the upregulation of
Snail (Fig. 3), which depended on activation of NF-κB
signaling (Fig. 5). Transcription factor Snail, which has
been implicated in NF-κB- regulated EMT process [22],
was evidenced to be one of the most important regula-
tors for E-cadherin regulation [9, 10]. Thus, upregulation
of MAGL in HCC cells enhanced Snail activity through
the activation of NF-κB signaling, which resulted in the
downregulation of E-cadherin and further triggered sub-
sequent EMT process.
Conclusions
In summary, we revealed a novel role for MAGL in the
regulation of EMT via NF-κB pathway in HCC. Overex-
pression of MAGL in HCC is a potential biomarker of
aggressive tumors and poor patient prognosis. Although
further clinical trials are needed to assess its safety and
effectiveness, our findings suggest that MAGL may be
an attractive therapeutic target for HCC.
(See figure on previous page.)
Fig. 2 MAGL enhances HCC cell growth and invasiveness in vivo and in vitro. a, b The protein and mRNA levels of MAGL in different
HCC cell lines (HepG2, SMMC7721, Huh7, MHCC97L, MHCC97H, and HCCLM3) and one normal liver cell line (L0-2). c, d Western blot and
qRT-PCR analysis showed the protein and mRNA expression of MAGL in HCC cells (HepG2-vector, HepG2-MAGL, HCCLM3-vector, and
HCCLM3-shMAGL). e MAGL overexpression promoted HCC progression in vivo. Xenograft model of HCC in nude mice were established as
described in the “Methods” section. The tumor volumes of subcutaneous tumors between the experiment and control groups exhibited
significant differences. f The motility of HCC cells was detected by scratch wound assay, and statistics are shown with a bar graph. g The
invasion ability of HCC cells was measured by transwell Matrigel invasion assay, and statistics are shown with a bar graph. Data, mean +
SD. **P < 0.01 and ***P < 0.001
Zhu et al. Journal of Hematology & Oncology  (2016) 9:127 Page 7 of 13
Methods
Patients and specimens
Tumor specimens (n = 27) were randomly collected from
HCC patients who received curative resection at Fudan
University Shanghai Cancer Center (Shanghai, People’s
Republic of China). A total of 170 patients who
underwent curative resection for primary HCC from
2005 to 2011 in the Liver Cancer Institute, Zhong Shan
hospital, Fudan University (Shanghai, People’s Republic
of China) were randomly enrolled. The detailed clinico-
pathological characteristics of these patients are pre-
sented in Table 1.
Fig. 3 MAGL promotes the progression of HCC by enhancing EMT. a The cellular morphology of HCC cell lines (HepG2-vector, HepG2-
MAGL, HCCLM3-vector, and HCCLM3-shMAGL). b Western blot assay revealed the expression of epithelial and mesenchymal markers, as
well as the transcription factors, in HCC cells with different MAGL expression (HepG2-vector, HepG2-MAGL, HCCLM3-vector, and HCCLM3-
shMAGL). c–g qRT-PCR analysis of E-cadherin, N-cadherin, Vimentin, Snail, Twist levels in the indicated cell lines. h Representative immunostaining
images of EMT markers using serial sections of tumor samples. Scale bar, 50 μm. Data represent the mean + SD. *P < 0.05, **P < 0.01, and ***P < 0.001
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No patient received any preoperative anticancer treat-
ment. Prior patient consent from each participant and
ethical approval from the Research Ethics Committee of
Fudan University Shanghai Cancer Center were
obtained. The detailed follow-up procedures were
described previously [28, 29].
Fig. 4 MAGL activated the NF-κB signal pathway in HCC cells. a, b The protein and mRNA expression of NF-κB p65 were evaluated in
the indicated four HCC cell lines by western blot and qRT-PCR analysis. HepG2-MAGL cells were cultured with MAGL-inhibitor JZL184
(1 μM) for 0, 0.5, 1, and 4 h. c Western blot analysis revealed that the total protein level of NF-κB p65 was significantly downregulated in
a time-dependent manner by the treatment of JZL184. d The phosphorylation of NF-κB p65 decreased in a time-dependent manner
when treated with JZL184. e MAGL-inhibitor JZL184 could not inhibit the expression of NF-κB p65 in cytoplasm as culture time extended.
f The expression of NF-kB p65 in the nucleus was significantly reduced in a time-dependent manner when treated with JZL184. Data,
mean + SD. *P < 0.05, **P < 0.01, and ***P < 0.001
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Fig. 5 MAGL facilitates EMT via the NF-κB signaling pathway. a Western blot assay showed the expression of NF-κB p65, Snail, and MAGL in HCC
cells with different MAGL expression (HepG2-vector, HepG2-OE). b–d qRT-PCR analysis of NF-κB p65, Snail, and MAGL expression in the indicated
cell lines. e Scratch wound assay revealed that the blockade of NF-κB p65 in HepG2 cells by p65-shRNA significantly suppressed MAGL-induced cell
migration. f Transwell Matrigel invasion assay indicated that NF-κB p65-shRNA treatment markedly reversed MAGL-induced invasion. Data, mean +
SD. **P < 0.01 and ***P < 0.001. OE overexpression
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Cell lines and morphological observation
Six HCC cell lines, HepG2 (American Type Culture
Collection), Huh7 (Japanese Cancer Research Bank),
SMMC7721 (the Second Military Medicine College,
Shanghai, China), MHCC97L, MHCC97H, and
HCCLM3 (the Liver Cancer Institute of Zhongshan
Hospital, Shanghai, China) were used in this study.
One normal liver cell line, L0-2 (American Type Cul-
ture Collection) served as a control. All cell lines
were incubated in high glucose Dulbecco’s modified
Eagle medium (DMEM; Invitrogen), supplemented
with 10% fetal bovine serum (FBS; Invitrogen) at 37 °C
under 5% CO2 in humidified incubator. The morphology
of HCC cells was assessed by phase microscopy (Leica).
Quantitative real-time PCR and western blot analyses
RNA isolation, quantitative real-time PCR (qRT-PCR),
and western blot analyses were performed as previously
described [30–32]. The primers and antibodies used are
listed in the Additional file 1: Tables S1 and S2,
respectively.
Tissue microarray and immunohistochemistry (IHC)
analyses
Tissue microarrays (TMA) were constructed with the
specimens collected from 170 HCC patients. Immu-
nohistochemistry protocols were described in our pre-
vious study [33]. The immunoreactive score system
(IRS) performed in this study has been described pre-
viously [34, 35]. The antibodies used in this study are
listed in the Additional file 1: Table S2. The quantifi-
cation of MAGL expression in TMA were evaluated
by the integrated optical density (IOD) as previously
described [36]. The median density of IOD was calcu-
lated and used as a cutoff value in subsequent
analyses.
Cell transfection
The short hairpin RNA (shRNA)-mediated stable silen-
cing technique was used to assess the functional role of
MAGL in HCC cells as previously described [37]. The
designed target sequence for MAGL was cloned into the
pLKO.1 TRC cloning vector (Additional file 1: Table S3).
Lentiviral particles were constructed through cotransfec-
tion of the shRNA plasmid and the lentiviral enveloping
and packaging plasmid (pMD2.G and psPAX2) into 293
T cells. The HCC cells were transfected with the viral
particles, and then selected with 2 mg/ml puromycin
(P8833; Sigma-Aldrich).
Cell migration assay
Cell migration assay was performed by the scratch
wound assay. HCC cells were cultured to form a tight
cell monolayer, and then wounded with 200-μl plastic
pipette tip. At 0 and 72 h, the migrating distance of
HCC cells at the wound front were analyzed by an
inverted microscope (Leica) for three randomly captured
images.
Cell matrigel invasion assay
Cell invasion assay were assessed using 24-well trans-
wells (8 μm pore size; Corning, USA) precoated with
Matrigel (Falcon354480; BD Biosciences, USA). HCC
cells placed in the upper chamber were suspended in
serum-free medium, and the lower chamber were added
with serum-containing medium. After 24 h of incuba-
tion, the cells on the lower surface of the Matrigel mem-
brane were fixed by paraformaldehyde, and then stained
with Giemsa. The quantity of cells were counted and
photographed at ×100 magnification. All experiments
were carried out in triplicate.
Animals and in vivo experiment
Male athymic BALB/c nude mice (4–6-weeks-old) were
obtained from Shanghai Institute of Material Medicine,
Chinese Academy of Science, and raised in specific
pathogen-free conditions. Animal care and experimental
protocols were performed according to the guidelines
approved by the Shanghai Medical Experimental Animal
Care Commission. Twenty mice were randomly divided
into four groups, and 1 × 107 HCC cells (HepG2-vector,
HepG2-MAGL, HCCLM3-vector, and HCCLM3-
shMAGL) in 0.2 ml normal saline were implanted by
subcutaneous injection to construct subcutaneous tu-
mors. Tumor dimensions were measured with vernier
calipers after 4 weeks, and then calculated by the for-
mula: tumor volume = (length × width2)/2.
Statistical analysis
Data was analyzed with SPSS 19.0 for Windows (IBM)
as previously described [38]. Differences among variables
were compared by Pearson’s chi-square test or Fisher’s
exact test. Overall survival (OS) was defined as the inter-
val between surgery and death or between surgery and
the last observation point. Time to recurrence (TTR)
was defined as the interval between surgery and recur-
rence. The data of patients experiencing death or alive
without recurrence were censored at the date of death
or the last follow-up, respectively [39]. The survival and
cumulative recurrence rates were performed by the
Kaplan–Meier method and calculated by the log-rank
test. The Cox proportional hazards regression model
was used to carry out univariate and multivariate ana-
lysis. All variables might be associated with OS or TTR
were subjected to the multivariate Cox analysis with 0.2
level for entry into the model. P < 0.05 was considered
statistically significant.
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N-cadherin, and Snail expression in HCCLM3 cells with different MAGL
expression levels. (PDF 303 kb)
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